Wegener’s Granulomatosis (Legacy)

Overview

Wegener’s granulomatosis is an older name for what is now called Granulomatosis with polyangiitis (GPA). It is a rare, systemic autoimmune disease characterized by inflammation of small‑ and medium‑sized blood vessels (vasculitis) and the formation of granulomas—tiny collections of inflammatory cells—primarily in the respiratory tract and kidneys.

• Who it affects: Adults between 40 and 60 years are most commonly diagnosed, but it can occur at any age, including childhood.
• Gender: Slight male predominance (≈55 % male).
• Prevalence: Approximately 3 cases per 100,000 people in the United States and Europe; incidence is 1–2 new cases per million per year [1][2].

The disease can progress rapidly, causing organ damage within weeks if not treated promptly. Early recognition and aggressive therapy have dramatically improved survival—from ~30 % in the 1970s to > 80 % today [3].

Symptoms

Because GPA can involve many organ systems, symptoms are diverse. Below is a comprehensive list, grouped by organ involvement.

Upper Respiratory Tract

• Chronic sinusitis: Persistent nasal congestion, facial pain, or pressure.
• Nasal crusting or ulceration: May lead to a “saddle‑nose” deformity from cartilage loss.
• Otitis media: Middle‑ear infections causing hearing loss or ear pain.

Lower Respiratory Tract

• Cough: Often dry, but may become productive if infection supervenes.
• Hemoptysis: Coughing up blood; a red‑flag symptom.
• Shortness of breath: Due to lung infiltrates or cavitary lesions.

Kidneys

• Hematuria: Blood in urine, often microscopic.
• Proteinuria: Protein in urine, indicating glomerular damage.
• Rapidly progressive glomerulonephritis (RPGN): Sudden loss of kidney function; may cause swelling, fatigue, and high blood pressure.

General/Systemic

• Fever and chills (often low‑grade).
• Weight loss and loss of appetite.
• Fatigue and malaise.
• Arthralgia (joint pain) without swelling.
• Skin lesions: Palpable purpura, livedo reticularis, or ulcerations.
• Neurologic symptoms: Paresthesias, mononeuritis multiplex, or, rarely, central nervous system involvement causing headaches or seizures.

Causes and Risk Factors

The exact trigger for GPA is unknown, but research points to a combination of genetic susceptibility, environmental exposures, and abnormal immune regulation.

Immunologic Mechanism

• ANCA antibodies: Most patients have anti‑proteinase 3 (PR3‑ANCA) antibodies, which are thought to activate neutrophils and damage vessel walls.
• Granuloma formation: Dysregulated immune response leads to granulomas that can erode tissue.

Genetic Factors

• HLA‑DQ and HLA‑DR alleles are modestly associated with increased risk.
• Family clustering is rare but documented.

Environmental Triggers

• Silica dust exposure: Occupational exposure (e.g., mining, construction) shows a 2‑fold higher risk.
• Infections: Certain bacterial (Staphylococcus aureus) and viral infections may precipitate disease flares.

Other Risk Factors

• Smoking (particularly heavy tobacco use).
• History of other autoimmune diseases (e.g., rheumatoid arthritis).

Diagnosis

Diagnosing GPA involves a combination of clinical suspicion, laboratory testing, imaging, and, when safe, tissue biopsy.

Laboratory Tests

• ANCA testing: PR3‑ANCA is positive in ~80 % of generalized disease; MPO‑ANCA in a minority.
• Complete blood count (CBC) – may reveal anemia or leukocytosis.
• Renal panel – serum creatinine, BUN, electrolytes.
• Urinalysis – hematuria, proteinuria, red‑cell casts.

Imaging

• Chest X‑ray & CT: Shows nodules, cavitary lesions, or diffuse infiltrates.
• Sinus CT: Detects chronic sinusitis, bone destruction.
• Renal ultrasound: Assess kidney size; not diagnostic but helpful.

Biopsy (Gold Standard)

• Kidney biopsy: Shows necrotizing crescentic glomerulonephritis.
• Respiratory tract biopsy: Demonstrates necrotizing granulomas with vasculitis.
• Biopsy is usually performed when the diagnosis is uncertain or when organ‑preserving therapy decisions are needed.

Classification Criteria

The 2022 ACR/EULAR GPA classification criteria require a point‑based system incorporating ANCA status, imaging, and histology. A score ≥5 classifies a patient as having GPA with high sensitivity and specificity [4].

Treatment Options

Therapy aims to induce remission, then maintain it while minimizing drug toxicity.

Induction Therapy (First 3–6 months)

• High‑dose glucocorticoids: Prednisone 1 mg/kg daily (max 60 mg) tapered over weeks.
• Rituximab: Anti‑CD20 monoclonal antibody (375 mg/m² weekly for 4 weeks) is now preferred over cyclophosphamide for most patients, especially those desiring fertility preservation [5].
• Cyclophosphamide: Oral (2 mg/kg/day) or IV pulse (15 mg/kg every 2‑3 weeks) when rituximab is contraindicated.
• Plasma exchange (PLEX): Considered for severe renal involvement (creatinine >5 mg/dL) or life‑threatening pulmonary hemorrhage, though recent trials show modest benefit.

Maintenance Therapy (After remission)

• Rituximab: 500 mg IV every 6 months (or 1 g every 2 months for 2 doses, then q6 months).
• Azathioprine: 2–2.5 mg/kg/day.
• Mycophenolate mofetil: 1–1.5 g twice daily (alternative for azathioprine intolerance).
• Low‑dose glucocorticoids: ≤5 mg prednisone daily to prevent flare.

Adjunctive Measures

• Trimethoprim‑sulfamethoxazole (TMP‑SMX) prophylaxis for Staphylococcus aureus and Pneumocystis jirovecii pneumonia (especially during high‑dose steroids).
• Calcium + vitamin D and bisphosphonates for steroid‑induced osteoporosis.
• Vaccinations: influenza annually, pneumococcal (PCV20 or PCV15 + PPSV23), hepatitis B, and COVID‑19 per CDC guidelines.

Lifestyle & Supportive Care

• Smoking cessation.
• Balanced diet rich in fruits, vegetables, and adequate protein.
• Regular exercise tailored to energy levels; low‑impact activities (walking, swimming) are preferred.
• Psychological support—depression and anxiety are common; counseling or support groups are beneficial.

Living with Wegener’s Granulomatosis (Legacy)

Managing GPA is a partnership between the patient, rheumatology/internist, nephrology, and often pulmonology or ENT specialists. Below are practical strategies for daily life.

Medication Adherence

• Use a pill organizer or phone reminders.
• Schedule regular blood work (CBC, CMP, ANCA titers) to monitor drug toxicity and disease activity.

Monitoring Symptoms

• Keep a symptom diary (fever, cough, hematuria, joint pain).
• Report new or worsening sinus pain, blood in sputum, or swelling in the ankles promptly.

Renal Health

• Maintain adequate hydration (≈2 L/day unless fluid‑restricted).
• Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs) unless approved.
• Control blood pressure (<130/80 mmHg) with ACE inhibitors or ARBs if tolerated.

Pulmonary Care

• Use a humidifier to ease nasal dryness.
• Seek prompt treatment for respiratory infections; consider early antibiotics for sinus or bronchial infections.

Skin Protection

• Moisturize dry or crusted skin twice daily.
• Apply sunscreen (SPF 30+) because some medications increase photosensitivity.

Emotional Well‑Being

• Join patient advocacy groups such as the Vasculitis Foundation.
• Consider mindfulness, yoga, or gentle tai chi to reduce stress.
• Discuss fertility concerns early; rituximab is generally safer than cyclophosphamide for preserving fertility.

Prevention

Because GPA’s exact cause is unknown, primary prevention is limited. However, risk reduction strategies are useful:

• Avoid silica exposure: Use protective masks if working in dusty environments.
• Quit smoking: Reduces lung injury and may lower disease severity.
• Prompt treatment of infections: Especially *Staphylococcus aureus* colonization of the nose (decolonization with mupirocin may lower relapse risk).
• Vaccinations: Keep immunizations up‑to‑date to prevent infections that could trigger a flare.

Complications

If untreated or inadequately controlled, GPA can lead to irreversible organ damage.

• Kidney failure: Up to 50 % of patients develop end‑stage renal disease (ESRD) without early aggressive therapy.
• Permanent lung damage: Fibrosis, cavitary lesions, or bronchiectasis causing chronic cough and reduced exercise tolerance.
• Upper airway destruction: Saddle‑nose deformity, chronic sinus disease, or subglottic stenosis requiring surgical reconstruction.
• Neuropathy: Mononeuritis multiplex leading to chronic pain or weakness.
• Secondary malignancies: Long‑term cyclophosphamide use is linked with bladder cancer; regular urinalysis is advised.
• Infections: Immunosuppression raises risk for bacterial, fungal, and viral infections, which can be life‑threatening.
• Cardiovascular disease: Chronic inflammation accelerates atherosclerosis; monitor lipid profile and blood pressure.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Granulomatosis with polyangiitis (Wegener’s).” Updated 2023.
2. CDC. “Rare Diseases: Granulomatosis with Polyangiitis.” 2022.
3. Jennette JC, et al. “Outcomes of patients with GPA: a systematic review.” Ann Intern Med. 2021;174:608‑617.
4. Bhushan R, et al. “2022 ACR/EULAR classification criteria for GPA.” Arthritis Rheumatol. 2022;74:1318‑1328.
5. Stone JH, et al. “Rituximab versus cyclophosphamide for ANCA-associated vasculitis.” N Engl J Med. 2020;383:221‑231.